NYSEAMERICAN:MTNB Matinas Biopharma (MTNB) Stock Price, News & Analysis $0.91 +0.05 (+6.35%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsOwnershipSEC Filings About Matinas Biopharma Stock (NYSEAMERICAN:MTNB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Matinas Biopharma alerts:Sign Up Key Stats Today's Range$0.87▼$0.9150-Day Range$0.86▼$3.0852-Week Range$0.81▼$17.40Volume5,849 shsAverage Volume55,963 shsMarket Capitalization$891.80 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Matinas BioPharma is a biopharmaceutical company focused on developing medicines using its lipid nanocrystal (LNC) delivery technology. The platform is designed to help deliver drugs that can be difficult to administer or absorb, including through oral formulations. The company’s development programs have included MAT2203, an oral formulation of amphotericin B studied for serious fungal infections, and MAT2501, an oral formulation of amikacin investigated for difficult-to-treat bacterial infections. These programs have been intended to offer alternatives to conventional routes of administration. Matinas has also explored its LNC platform for delivering other types of therapeutics. Its work has primarily centered on drug development rather than selling a broad range of commercial medicines.AI Generated. May Contain Errors. Read More Matinas Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreMTNB MarketRank™: 1.47046952778 of 5 starsMatinas Biopharma scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Matinas Biopharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Matinas Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Matinas Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMatinas Biopharma has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.80% of the float of Matinas Biopharma has been sold short.Short Interest Ratio / Days to CoverMatinas Biopharma has a short interest ratio ("days to cover") of 0.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Matinas Biopharma has recently decreased by 28.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMatinas Biopharma does not currently pay a dividend.Dividend GrowthMatinas Biopharma does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.69 News SentimentMatinas Biopharma has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Matinas Biopharma this week, compared to 0 articles on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Matinas Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders4.60% of the stock of Matinas Biopharma is held by insiders.Percentage Held by Institutions11.77% of the stock of Matinas Biopharma is held by institutions.Read more about Matinas Biopharma's insider trading history. Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTNB Stock News HeadlinesMatinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 17 at 1:42 PM | marketscreener.comMGH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility OutputSeptember 14, 2026 | globenewswire.comYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn $100 Options Into $1,000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.November 18 at 1:00 AM | TradeWins (Ad)Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsSeptember 4, 2026 | globenewswire.comGH Power, Matinas BioPharma join forces to create NYSE-listed clean energy companyJuly 13, 2026 | msn.comMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement ...July 13, 2026 | markets.businessinsider.comMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity PharmaceuticalsJuly 13, 2026 | globenewswire.comMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain ComplianceJune 26, 2026 | globenewswire.comSee More Headlines MTNB Stock Analysis - Frequently Asked Questions How have MTNB shares performed this year? Matinas Biopharma's stock was trading at $8.79 at the start of the year. Since then, MTNB stock has decreased by 89.6% and is now trading at $0.91. How were Matinas Biopharma's earnings last quarter? Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings data on Monday, November, 16th. The company reported ($9.35) earnings per share (EPS) for the quarter. When did Matinas Biopharma's stock split? Matinas Biopharma's stock reverse split on the morning of Monday, September 28th 2026.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, September 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Matinas Biopharma? Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Matinas Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include SCYNEXIS (SCYX), Tesla (TSLA), Viking Therapeutics (VKTX), Kushco (KSHB), Oncobiologics (OTLK), NIO (NIO) and Bionano Genomics (BNGO). Company Calendar Last Earnings11/16/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MTNB's financial health is in the Red zone, according to TradeSmith. MTNB has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:MTNB Previous SymbolNYSE:MTNB CIK1582554 Webmatinasbiopharma.com Phone(908) 484-8805FaxN/AEmployees2Year Founded2011Profitability EPS (Trailing Twelve Months)($3.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-215.21% Return on Assets-125.94% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$1.10 million Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value$11.30 per share Price / Book0.08Miscellaneous Outstanding Shares980,000Free Float935,000Market Cap$891.80 thousand OptionableN/A Beta2.24 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NYSEAMERICAN:MTNB) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.